Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31424923 | 0.85 | MEN1 (0.74) | HDAC1HDAC7MEN1KMT2AHDAC6 | |
| SCHEMBL28462499 | 0.84 | HDAC1 (0.72) | HDAC1HDAC7HDAC6HDAC2HDAC3 | |
| SCHEMBL16039000 | 0.84 | HDAC1 (0.72) | HDAC1HDAC7MEN1KMT2AHDAC2 | |
| SCHEMBL1365105 | 0.83 | HDAC1 (0.70) | HDAC1HDAC7HDAC6HDAC2HDAC3 | |
| SCHEMBL8221904 | 0.82 | HDAC1 (0.70) | HDAC1HDAC7MEN1KMT2AHDAC6 | |
| SCHEMBL16038134 | 0.82 | HDAC1 (0.69) | HDAC1HDAC7MEN1KMT2AHPGD | |
| SCHEMBL31753078 | 0.82 | KMT2A (0.74) | HDAC1HDAC7MEN1KMT2AHPGD | |
| SCHEMBL916927 | 0.82 | KMT2A (0.74) | HDAC1HDAC7MEN1KMT2AHPGD | |
| SCHEMBL1364992 | 0.82 | HDAC1 (0.68) | HDAC1HDAC7HDAC6HDAC2HDAC3 | |
| SCHEMBL18537332 | 0.81 | HDAC1 (0.71) | HDAC1HDAC7MEN1KMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2011-01-06 | — | — | US | claimed |
| EP-2045239-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | Universidad De Granada (ES) | 2009-04-08 | — | — | EP | claimed |
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2011-01-06 | — | — | US | disclosed |
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2011-01-06 | — | — | US | disclosed |
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2011-01-06 | — | — | US | disclosed |
| EP-2045239-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | Universidad De Granada (ES) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003801-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003878-A1 | NOVEL DERIVATIVES OF PHTHALIMIDE AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC7 10/4885MEN1 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.